Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 94

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 94
---
 Requirement. Normally, a company would be afforded a 180-calendar
day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to NASDAQ Listing Rule 5810(c)(3)(A)(iv),
we were not eligible for any compliance period specified in Rule 5810(c)(3)(A) because we effected reverse stock splits over the prior
two-year period with a cumulative ratio of 250 shares or more to one. Accordingly, and as described in the Letter, unless we timely requested
a hearing before the Panel, our securities would be subject to suspension/delisting. We requested a hearing, which automatically stayed
any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following
the hearing.

On October 14, 2024, the Panel
granted our request for an extension of time to demonstrate compliance with the Minimum Bid Price Requirement. On November 7, 2024, we
were formally notified that the Panel determined that we had regained compliance with the Minimum Bid Price Requirement. We remain subject
to a discretionary panel monitor through February 24, 2025, and we are required to provide prompt notification during this exception period
of any significant events that occur during this time that may affect our compliance with NASDAQ requirements.

While we have regained compliance
with all applicable requirements for continued listing on the NASDAQ Capital Market, we cannot assure you that we will remain in compliance
with all applicable requirements for continued listing on the NASDAQ Capital Market. If, in the future, we fail to sustain compliance
with all applicable requirements for continued listing on NASDAQ, including during the one-year monitoring period, our Depositary Shares
may be subject to delisting by NASDAQ. This could inhibit the ability of our holders of Depositary Shares to trade their shares in the
open market, thereby severely limiting the liquidity of such shares. Although holders may be able to trade their shares of Depositary
Shares on the over-the-counter market, there can be no assurance that this would occur. Further, the over-the-counter market provides
significantly less liquidity than NASDAQ and other national securities exchanges, is thinly traded and highly volatile, has fewer market
makers and is not followed by analysts. As a result, your ability to trade or obtain quotations for these securities may be more limited
than if they were quoted on NASDAQ or other national securities exchanges.

The price of our Depositary Shares may be volatile.

The trading price of our Deposit